caa a22 4500 477057853 CHVBK 20180405111351.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00195930 doi (NATIONALLICENCE)springer-10.1007/BF00195930 Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril [Elektronische Daten] [S. Antila, L. Lehtonen, E.-P. Sandell, J. Eha, M. Heinpalu, I. Loogna, A. Mesikepp, U. Planken] Objective: Levosimendan in a new inodilator drug that sensitises troponin C in heart muscle cells to calcium, thus improving contractility. In previous studies, a single 2 mg intravenous dose of levosimendan increased cardiac output (CO) in healthy volunteers by about 40% and decreased pulmonary capillary wedge pressure in heart failure patients by 40-50%. The aim of the present, double-blind study was to evaluate the safety of concomitant use of levosimendan and an ACE-inhibiting drug. Methods: The haemodynamic effects of levosimendan, given with or without captopril, were evaluated by using 2-dimensional echocardiography, repeated blood pressure measurements and by ambulatory ECG recordings. Twenty-four male patients with stable NYHA II-III heart failure (EF<40%) after a previous myocardial infarct were given, in randomised order, a single IV infusion of levosimendan or placebo. The infusions were repeated after 2 weeks treatment with upto 50 mg b.i.d. of captopril. Twelve patients received levosimendan 1 mg and twelve received 2 mg. Results: Mean CO was increased from 6.0 to 6.81·min−1 in patients receiving 1 mg levosimendan compared to placebo, but only from 6.3 to 6.51·min−1 in patients receiving 2 mg. The increase in CO was statistically significant when all levosimendan patients were compared to placebo. Heart rate did not change after either dose. Mean stroke volume increased significantly after 1 mg but not after 2 mg of levosimendan. The addition of captopril did not change the effects of levosimendan. No additional decrease in systolic or diastolic blood pressure was observed when levosimendan and captopril were given concomitantly. Conclusion: It seems that concomitant treatment with captopril does not change the haemodynamic effects of levosimendan. No adverse haemodynamic interactions were seen. Springer-Verlag, 1996 Levosimendan nationallicence Captopril nationallicence calcium sensitizer nationallicence inotropic drugs nationallicence haemodynamics nationallicence heart failure nationallicence drug interaction nationallicence Antila S. Orion-Farmos, Orion Research, P.O. Box 65, SF-02101, Espoo, Finland aut Lehtonen L. Orion-Farmos, Orion Research, P.O. Box 65, SF-02101, Espoo, Finland aut Sandell E.-P Orion-Farmos, Orion Research, P.O. Box 65, SF-02101, Espoo, Finland aut Eha J. Estonian Heart Center, Tallinn, Estonia aut Heinpalu M. Estonian Heart Center, Tallinn, Estonia aut Loogna I. Estonian Heart Center, Tallinn, Estonia aut Mesikepp A. Estonian Heart Center, Tallinn, Estonia aut Planken U. Estonian Heart Center, Tallinn, Estonia aut European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 451-458 0031-6970 49:6<451 1996 49 228 https://doi.org/10.1007/BF00195930 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00195930 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Antila S. Orion-Farmos, Orion Research, P.O. Box 65, SF-02101, Espoo, Finland aut NATIONALLICENCE 700 1- Lehtonen L. Orion-Farmos, Orion Research, P.O. Box 65, SF-02101, Espoo, Finland aut NATIONALLICENCE 700 1- Sandell E.-P Orion-Farmos, Orion Research, P.O. Box 65, SF-02101, Espoo, Finland aut NATIONALLICENCE 700 1- Eha J. Estonian Heart Center, Tallinn, Estonia aut NATIONALLICENCE 700 1- Heinpalu M. Estonian Heart Center, Tallinn, Estonia aut NATIONALLICENCE 700 1- Loogna I. Estonian Heart Center, Tallinn, Estonia aut NATIONALLICENCE 700 1- Mesikepp A. Estonian Heart Center, Tallinn, Estonia aut NATIONALLICENCE 700 1- Planken U. Estonian Heart Center, Tallinn, Estonia aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 451-458 0031-6970 49:6<451 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer